Evidence map›Paper›PMID 26288830›Full record

ArticleEBioMedicine2015

Rethinking the Antibiotic Discovery Paradigm.

Robert E W Hancock

Abstract readComment
In one paragraph

Article in EBioMedicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Identification of novel targets of azithromycin activity againstProceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  7. Article
  8. Journal of fungi (Basel, Switzerland) · 2019
    Review
  9. Review
  10. Article
  11. Article
  12. Synthetic antibiofilm peptides.Biochimica et biophysica acta · 2016
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Robert E W HancockCentre for Microbial Diseases and Immunity Research, University of British Columbia, Vancouver, British Columbia V6T 1Z4, Canada.

Funding

Novel adjunctive therapy for drug resistant Gram-negative pathogensR21AI098701 · NIAID · UNIVERSITY OF BRITISH COLUMBIA · PI HANCOCK, ROBERT ERNEST WILLIAM · 2012 to 2013
$297k
NIAID NIH HHS R21 AI098701NIAID NIH HHS R21AI098701
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsAnti-Bacterial AgentsAntimicrobial Cationic PeptidesAzithromycinDrug Resistance, Multiple, BacterialFemaleGram-Negative BacteriaHumansAnti-Bacterial AgentsAntimicrobial Cationic PeptidesAzithromycin

Identifiers

PMID26288830
PMCPMC4534705

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.